Literature DB >> 4522797

Migration enhancement factor: a new lymphokine.

R H Weisbart, R Bluestone, L S Goldberg, C M Pearson.   

Abstract

Production of human migration inhibitory factor by lymphocytes exposed to antigen was studied at intervals over a 7-day period. Migration inhibitory factor was measured by an agarose gel method, with buffycoat leukocytes as indicator cells. Lymphocyte supernatants from 7-day cultures consistently showed migration inhibitory factor activity; by contrast, enhancement of migration was frequently noted when effector cells were exposed to supernatants from 2- to 5-day cultures. Enhancement activity was manifested either by enhanced migration or by a sequential reduction in inhibitory activity consistent with a factor opposing the action of migration inhibitory factor. When supernatants were subjected to polyacrylamide gel electrophoresis, enhancement activity was regularly found in the beta-globulin region and migration inhibitory factor in the albumin fraction of the gel. The enhancement activity was heat-stable and nondialyzable. These findings characterize a hitherto unreported lymphokine, migration enhancement factor.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4522797      PMCID: PMC388118          DOI: 10.1073/pnas.71.3.875

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  7 in total

1.  In vitro cell migration as a model for delayed hypersensitivity.

Authors:  M GEORGE; J H VAUGHAN
Journal:  Proc Soc Exp Biol Med       Date:  1962-11

2.  A modified agarose method for detection of migration inhibitory factor and delineation of its antigen dependency.

Authors:  R H Weisbart; J E Cunningham; R Bluestone; L S Goldberg
Journal:  Int Arch Allergy Appl Immunol       Date:  1973

3.  A simplified method for lymphocyte separation.

Authors:  R H Weisbart; W F Webb; R Bluestone; L S Goldberg
Journal:  Vox Sang       Date:  1972       Impact factor: 2.144

4.  Cell migration inhibition factor released by antigen from human peripheral lymphocytes.

Authors:  D E Thor; R E Jureziz; S R Veach; E Miller; S Dray
Journal:  Nature       Date:  1968-08-17       Impact factor: 49.962

5.  'Lymphokines': molecular mediators of cellular immune responses in animals and man.

Authors:  D C Dumonde
Journal:  Proc R Soc Med       Date:  1970-09

6.  Mechanism of a reaction in vitro associated with delayed-type hypersensitivity.

Authors:  B R Bloom; B Bennett
Journal:  Science       Date:  1966-07-01       Impact factor: 47.728

7.  Studies on migration inhibitory factor (MIF): recovery of MIF activity after purification by gel filtration and disc electrophoresis.

Authors:  H G Remold; A B Katz; E Haber; J R David
Journal:  Cell Immunol       Date:  1970-05       Impact factor: 4.868

  7 in total
  23 in total

1.  Lymphocyte response to IgG in patients with ankylosing spondylitis and their families.

Authors:  R H Weisbart; R I Morris; P I Terasaki; R Bluestone; L S Goldberg
Journal:  Clin Exp Immunol       Date:  1976-12       Impact factor: 4.330

2.  Mediation of macrophage effector function by lymphokine.

Authors:  L W Poulter; J L Turk
Journal:  Agents Actions       Date:  1976-02

3.  In vitro cellular immunity in Chagas' disease.

Authors:  M A Toledo Barros; V Amato Neto; E Mendes; I Mota
Journal:  Clin Exp Immunol       Date:  1979-11       Impact factor: 4.330

4.  Comparison of a leucocyte adherence test with the leucocyte migration inhibition test and skin reactivity to PPD.

Authors:  A W Bullen; M S Losowsky
Journal:  Clin Exp Immunol       Date:  1978-03       Impact factor: 4.330

5.  Modification by soluble antigen of the immune response to mycobacterial infection.

Authors:  P G Holt; P J Fimmel; L M Roberts; D Keast
Journal:  Infect Immun       Date:  1977-06       Impact factor: 3.441

6.  Induction of a macrophage migration enhancement factor after desensitization of tuberculin-positive rabbits with purified protein derivative.

Authors:  M R Gordon; I Takata; Q N Myrvik
Journal:  Infect Immun       Date:  1986-01       Impact factor: 3.441

7.  Leukocyte migration inhibitory factor (LMIF) induced by concanavalin A: standardized microassay for production in vitro.

Authors:  A J Górski; B Dupont; J A Hansen; R A Good
Journal:  Proc Natl Acad Sci U S A       Date:  1975-08       Impact factor: 11.205

8.  Immunoassessment of patients with gastric cancer. Using leukocyte migration inhibition (LMI) test.

Authors:  O Kojima; Y Uehara; T Majima; E Ikeda; B Nishioka; Y Fujita; S Majima
Journal:  Gastroenterol Jpn       Date:  1983-08

9.  Leucocyte migration inhibition by tumour-associated antigens in human bladder carcinoma.

Authors:  D F Meleady; M R Butler; J F Greally; G M Mullins
Journal:  Ir J Med Sci       Date:  1980-10       Impact factor: 1.568

10.  Alterations in mouse macrophage migration: a function of assay systems, lymphocyte activation product preparation, and fractionation.

Authors:  P L Sandok; R D Hinsdill; R M Albrecht
Journal:  Infect Immun       Date:  1975-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.